Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
| ▸ | CCR8 | P51685 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208300 | 1.00 | CCR1 (0.55) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL7330317 | 0.82 | CCR1 (0.57) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL16179703 | 0.81 | ALDH1A1 (0.59) | ALDH1A1ERN1CYP2A6NFE2L2DYRK1A | |
| SCHEMBL29956732 | 0.81 | NQO1 (0.41) | NOS1NOS2ALDH1A1KDM4ENPSR1 | |
| SCHEMBL19282141 | 0.81 | NQO1 (0.41) | NOS1NOS2ALDH1A1KDM4ENPSR1 | |
| SCHEMBL24573019 | 0.80 | DYRK1A (0.60) | ALDH1A1KDM4EMAPK1ERN1CYP2A6 | |
| SCHEMBL931557 | 0.80 | CCR1 (0.55) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL11096737 | 0.80 | CCR1 (0.55) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL17356164 | 0.80 | CCR1 (0.32) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL28173060 | 0.80 | CCR1 (0.55) | CCR1CCR5CCR8NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| CN-119039275-A | Preparation method of biologically active imidazole derivative 2,3, 5-tripyridine substituted imidazole | 武汉理工大学深圳研究院 | 2024-11-29 | — | — | CN | claimed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| CN-120025304-A | Method for preparing cyclic ether based on propargyl compound | 南京师范大学 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025080653-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUNDS ACTING AGAINST CANCERS, INFLAMMATORY DISEASES, AND FIBROTIC DISEASE VIA INTERACTION WITH RAS SUPERFAMILY PROTEINS | SHY THERAPEUTICS, LLC (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119039275-A | Preparation method of biologically active imidazole derivative 2,3, 5-tripyridine substituted imidazole | 武汉理工大学深圳研究院 | 2024-11-29 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024022313-A1 | METHOD FOR SITE-DIRECTED SYNTHESIS OF PROTEIN-ACTIVE MOLECULAR CONJUGATE | 南京金斯瑞生物科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2024022315-A1 | METHOD FOR PURIFYING PROTEIN-NUCLEIC ACID CONJUGATE | 南京金斯瑞生物科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| EP-4096661-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CCR1 4485/4885CCR5 4295/4885CCR8 4585/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | CCR1 1712/4885CCR5 1934/4885CCR8 3004/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CCR1 4485/4885CCR5 4295/4885CCR8 4585/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CCR1 4485/4885CCR5 4295/4885CCR8 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.